A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

December 8, 2021

Study Completion Date

January 27, 2022

Conditions
Lewy Body DiseaseParkinson Disease
Interventions
DRUG

E2027

Oral hypromellose capsules.

Trial Locations (14)

10032

Columbia University Medical Center, New York

12208

Neurological Associates of Albany, PC, Albany

33064

Napa Research, Pompano Beach

33155

Elias Research Associates (Allied Biomedical Research Institute), Miami

33414

Alzheimer's Research and Treatment Center, Wellington

33462

JEM Research Institute, Atlantis

33613

University of South Florida, Department of Psychiatry and Behavioral Neurosciences, Tampa

40536

University of Kentucky, Dept of Neurology, Sanders Brown Center on Aging, Lexington

44107

Cleveland Clinic, Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood

45459

Neurology Diagnostics, Inc., Dayton

85351

Banner Sun Health Research Institute, Sun City

97210

Summit Research Network (Oregon) Inc., Portland

08755

Advanced Memory Research Institute of NJPC, Toms River

M3B 2S7

Toronto Memory Program, Toronto

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT04764669 - A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology | Biotech Hunter | Biotech Hunter